(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo(d)imidazol-2-yl)-2-methylisonicotinamide,
EGF-816,
EGF816,
nazartinib,
nazartinib,
EGF816,
1508250-71-2,
EGF-816,
UNII-KE7K32EME8,
KE7K32EME8,
CHEMBL3787344,
Nazartinib (EGF816, NVS-816),
(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide,
EGF816; NVS-816;N-[7-chloro-1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamide,
N-{7-chloro-1-[(3R)-1-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-1H-1,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide,
NVS-816,
EGF 816,
Nazartinib [USAN],
Nazartinib(EGF816),
NVP-EGF816-NX,
nazartinib-egf816-nvs-816,
GTPL9204,
SCHEMBL16767232,
SCHEMBL16767240,
EX-A1640,
BDBM50160870,
s7824,
AKOS030632782,
ZINC210610738,
ACN-041462,
compound 47 [PMID: 27433829],
AC-29881,
HY-12872,
B5889,
J3.535.960E,
A14416,
4-Pyridinecarboxamide, N-[7-chloro-1-[(3R)-1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]hexahydro-1H-azepin-3-yl]-1H-benzimidazol-2-yl]-2-methyl-,
CS-4325,